Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Nazzareno Cervelli; Giuliano Tocci; Claudio Ferri

首页> 外文期刊>High blood pressure & cardiovascular prevention : >Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

【24h】

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

机译：Proprotein转化酶枯草杆菌蛋白酶-Kexin型9（PCSK9）抑制剂和心血管风险：进一步分析傅里叶试验表明脂质降低治疗目标的变化吗？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《High blood pressure & cardiovascular prevention :》 |2018年第1期|共3页
作者
Nazzareno Cervelli; Giuliano Tocci; Claudio Ferri;
展开▼
作者单位

Department of MeSVA University of L’Aquila;

The Italian Society of Hypertension (SIIA);

Department of MeSVA University of L’Aquila;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
专利

1. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? [J] . Nazzareno Cervelli, Giuliano Tocci, Claudio Ferri High blood pressure & cardiovascular prevention : . 2018,第1期

机译：Proprotein转化酶枯草杆菌蛋白酶-Kexin型9（PCSK9）抑制剂和心血管风险：进一步分析傅里叶试验表明脂质降低治疗目标的变化吗？
2. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial [J] . Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis, Metabolism: Clinical and Experimental . 2017,第期

机译：ProProtein转化酶枯草杆菌蛋白酶蛋白酶-Kexin型9（PCSK9）抑制剂：在进一步的心血管结果与PCSK9抑制升高风险（傅里叶）试验中的抑制后塑造未来
3. Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial) [J] . Wong Nathan D. The American Journal of Cardiology . 2017,第7期

机译：用Proprotein转化酶枯草杆菌蛋白酶-kexin患者治疗动脉粥样硬化性心血管疾病患者后的残留风险（从升高风险试验中的受试者中的PCSK9抑制的进一步心血管结果研究）
4. PCSK9 polymorphism rs505151 affects lipid-lowering response to atorvastatin but does not influence ezetimibe therapy in Chilean subjects [C] . Zambrano T, Caama?o JM, Rosales A, International Congress on Coronary Artery Disease . 2011

机译：PCSK9多态性RS505151影响到阿托伐他汀的降脂响应，但不会影响智利受试者的ezetimibe治疗
5. ACE inhibitor therapy for primary prevention of cardiovascular morbidity and mortality in patients with type 2 diabetes. [D] . Eurich, Dean T. 2003

机译：ACE抑制剂疗法可用于一级预防2型糖尿病患者的心血管发病率和死亡率。
6. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER SPIRE and the Cholesterol Treatment Trialists Collaboration [O] . Brian A Ference, Christopher P Cannon, Ulf Landmesser, -1

机译：前蛋白转化酶枯草杆菌素-kexin 9型（PCSK9）抑制剂和他汀类药物可降低低密度脂蛋白胆固醇和心血管事件：FOURIERSPIRE和胆固醇治疗试验师合作的分析
7. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [O] . Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, 2017

机译：基于傅立叶试验的钙蛋白转化酶枯草杆菌素/ kexin型9型抑制剂及相关成本的估算（进一步心血管结果与升高风险升高的受试者中的PCSK9抑制）

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

著录项

相似文献

相关主题

期刊订阅